Ascentage Pharma Group International (NASDAQ:AAPG) Shares Up 8.1% – Here’s What Happened

Posted by Brenda Bartman on May 20th, 2026

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG – Get Free Report)’s share price was up 8.1% during trading on Wednesday . The company traded as high as $19.31 and last traded at $20.07. Approximately 368 shares traded hands during mid-day trading, a decline of 90% from the average daily volume of 3,727 shares. The stock had previously closed at $18.56.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on AAPG shares. Deutsche Bank Aktiengesellschaft started coverage on Ascentage Pharma Group International in a research note on Friday, April 24th. They issued a “buy” rating and a $40.00 price objective on the stock. BTIG Research reaffirmed a “buy” rating and issued a $48.00 price objective on shares of Ascentage Pharma Group International in a research note on Monday, April 13th. Finally, China Intl Cap raised Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, April 6th. Two investment analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $46.67.

Read Our Latest Stock Report on Ascentage Pharma Group International

Ascentage Pharma Group International Trading Up 5.7%

The company has a current ratio of 1.79, a quick ratio of 1.77 and a debt-to-equity ratio of 0.57. The stock’s 50-day simple moving average is $23.67 and its 200 day simple moving average is $26.43.

Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) last issued its quarterly earnings results on Wednesday, March 25th. The company reported ($0.52) EPS for the quarter. The business had revenue of $24.72 million for the quarter. As a group, sell-side analysts predict that Ascentage Pharma Group International – Unsponsored ADR will post -1.09 EPS for the current year.

Institutional Trading of Ascentage Pharma Group International

Several large investors have recently modified their holdings of the stock. UBS Group AG grew its position in shares of Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after buying an additional 10,988 shares during the period. XY Capital Ltd grew its position in shares of Ascentage Pharma Group International by 224.2% during the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after buying an additional 12,530 shares during the period. Hsbc Holdings PLC acquired a new stake in shares of Ascentage Pharma Group International during the 2nd quarter worth approximately $391,000. Citadel Advisors LLC acquired a new stake in shares of Ascentage Pharma Group International during the 3rd quarter worth approximately $383,000. Finally, ABC Arbitrage SA acquired a new stake in shares of Ascentage Pharma Group International during the 3rd quarter worth approximately $204,000.

About Ascentage Pharma Group International

(Get Free Report)

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.